Mesenchymal stem cells (MSCs) represent a new tool for delivery of therapeutic agents to cancer sites due to their strong tropism toward tumors. has demonstrated a potent anti-tumor activity in various animal models as well as clinical trials. However, because of its short half-life, effective therapeutic effects usually require 
Introduction
The administration of cytokines to augment immunosurveillance has been proven to have efficacy in the treatment of several cancers (1) . IL-15 is a member of the common -chain family of cytokines and is functionally similar to IL-2 (2-4). Besides, IL-15 does not promote activation-induced cell death and does not induce proliferation of T regulatory cells, while maintaining long-lasting T-cell anti-tumor immunity, thus can potentially be a better tool for cancer immunotherapy (5) (6) (7) . Local and systemic administration of IL-15 protein has demonstrated promising anti-tumor effect in various animal models as well as human clinical trials (8, 9) . However, one limitation of IL-15 in exerting an efficacious antitumor effect is that due to its short half-life in plasma,usually high dose and repeated injections are needed to achieve meaningful responses in vivo (10, 11) . High level of IL-15 in blood could lead to undesired side effects, including NK and T cell leukemias, and organ-autoimmunity (12, 13) . Thus, an alternative administration approach which could avoid systemic toxicity of IL-15 and keep a focused concentration in tumor specific site is high necessary. MSCs differ depending on their sources, such as bone marrow (BM), umbilical cord blood (UCB), or adipose tissue (22) . UCB -derived MSCs have clinical advantages because of the immaturity of newborn cells compared with adult cells, large ex vivo expansion capacity, low risk of viral infection, lack of donor attrition, and less pronounced immune response (23, 24) . These advantages may result in the replacement of other adult stem cells with UCB-MSCs as the vehicle of choice in gene therapy against tumor.
Pancreatic adenocarcinoma (PDAC) is among the most fatal cancers, with a mortality rate approximates its incidence rate. The all-stage 5-year survival, which is about 5%, has remained unchanged over the last 25 years (25, 26) . In contrast to other malignancies, PDAC is highly resistant to chemotherapy and targeted therapy. Therefore, novel therapies such as immunotherapy which could improve the prognosis of patients with advanced PDAC are urgently needed (27) . Up to date, limited information was available regarding IL-15's antitumor role in pancreatic cancer. Thus, in this study, we investigated whether UCB-MSCs transfected with a lentivirus vector expressing murine IL-15 (MSC-IL-15), would represent an efficient IL-15 delivery system, and further evaluated the antitumor activity and long-term protective immunity of IL-15-expressing MSCs in a syngeneic mouse model of Pan02 pancreatic tumors. The UCB samples were obtained from the umbilical vein immediately after delivery.
Materials and methods

Isolation
Informed consent were received from the mothers and this study was approved by Institutional Review Board of the Changhai and PLA 301 Hospital. Isolation andculture of MSCs were conducted as previously reported (28) . Briefly, the UCB samples were mixed with Hetasep solution (StemCell Technologies, Vancouver, Canada) at a ratio of 5:1, and then incubated at room temperature to deplete erythrocyte counts. The supernatant was collected carefully and mononuclear cells were obtained using Ficoll (GE healthcare life sciences, Pittsburgh, PA) densitygradient centrifugation at 2500 rpm for 20 minutes. Cells were washed twice in PBS. Cells were then seeded at a density of To ascertain the in vitro differentiation ability, the 3rd passages of MSCs were cultured in osteogenic, adipogenic, and chondrogenic differentiation medium, respectively (Cyagen Biosciences Inc). To observe the calcium deposition, the cultured cells were fixed with 4% paraformaldehyde, and stained with Alizarin Red S. To 
Lentivirus vector expressing IL-15 construction and transduction
Replication defective lentivirus encoding the complete IL-15 open reading frame (LV-15) and a lentivirus vector encoding green Àuorescent protein (LV-GFP), which was used as the control, were constructed by Invitrogen. The 3rd-5th passages of MSCs were transduced with lentivirus at a multiplicity of infection (MOI) of 50 pfu per cell in 2% FBS medium with 10 ug »mL Polybrene (Sigma-Aldrich). At 24 h after transfection, 1
×10
6 cells were harvested and determined for IL-15 mRNA expression using RT-PCR.
The culture supernatants were collected and tested for IL-15 protein secretion using the ELISA method in accordance with the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA). One week later, cells were harvested by tryspinization and resuspended in PBS for injection. (Invitrogen, Cergy Pontoise, France) supplemented with 5% fetal bovine serum (Invitrogen) and 2 mM L-glutamine (Invitrogen). Cells were seeded at a density of 2× 105 cells/cm2 and incubated at 37 ͠ with 5% CO2 and 95% humidity. Six-week-old specific pathogen-free male C57BL/6 mice were purchased from Second Military Medical University, Shanghai, China. All animals in this study were housed under pathogen-free conditions and were maintained in accordance with guidelines of the 
Determination of bioactivity of IL-15 secreted by MSCs
Histology
Tumor tissues were collected at the indicated time, fixed in 10% neutral formalin, embedded in paraffin, and stained with hematoxylin and eosin (H&E 
In vivo cell depletion experiment
For NK and/or CD8 + T-cell deletion, mice received the following monoclonal antibodies (mAb) via intraperitoneal injection: anti-asialo-GM1 500 ug/injection, and 
CTL assays
Rechallenging experiment and adoptive transfer experiment
For tumor rechallenge experiments, C57BL/6 mice treated with MSC-IL-15 that survived for more than 100 days were rechallenged by contralateral injection of 1 × 10 6
Pan02 tumor cells. The injection site was proximal to (but not the same as) the initial injection site. 1 × 10 6 B16 tumor cells were challenged as controls. After the rechallenge and challenge, the tumor size and animal survival were measured as described above.
For adoptive transfer experiments, splenocytes were isolated from tumor-free mice. 
ELISA
Cell-free supernatants and tumor tissue homogenates were harvested and analyzed for the production of IL-15 and IFN-Ȗ by using ELISA kits (R&D Systems).
Statistical analysis
Data were compiled as mean ± SE in quantitative experiments. Two-way ANOVA was conducted. Statistical significance was determined at the p< 0.05 level. Survival estimates were determined using Kaplan and Meier method.
Results
Isolation and identification of UCB-MSCs
According to previous reports (22, 23) , we identified the characteristics of isolated UCB-MSCs, including fibroblastic-like morphology, immunophenotype, and Oil-Red-O staining in UCB-MSCs after incubation with the adipogenic supplementation for 21 days. Positive staining of Alizarin Red S was shown after osteogenic induction.Also blue staining indicated synthesis of proteoglycans by chondrocytes after chondrogenic induction (Fig. 1C) . Collectively, these data demonstrated that we successfully obtained abundant MSCs from human umbilical cord blood.
To determine whether immunocompetent cell contamination might exsist in MSC culture, we performed a more extended phenotypic characterization of MSCs by analyzing the expression of CD14, CD11b and CD16. As shown in supplementary figure   1 , the monocytic marker CD14, macrophage marker CD11b, and NK marker CD16 were not detected in the MSCs.
UCB-MSCs can be successfully transduced to release functional IL-15
UCB-MSCs were transduced with lentivirus encoding green fluorescent protein (MSC-GFP) or GFP together with mouse IL-15 (MSC-15).Over 90% cells were successfully transduced, as shown by GFP expression (Fig. 2A) showed that membrane-bound IL-15 was not detected (Fig. 2D) .
We further determined whether IL-15 produced by MSC-IL-15 was biofunctional.
First, splenocytes were cultured in the culture supernatants of MSC-IL-15, and proliferation was followed by MTT metabolization assays (Fig. 2E) . The results showed that splenocytes could continue to proliferate compared with the group treated with the culture supernatants of MSC-GFP. To investigate whether IL-15 produced by MSC-IL-15 was able to activate lymphocyte cells, we analyzed phosphoration of STAT5 and STAT3 (10, 28) , which act as signal transducers downstream of IL-2/IL-15 receptors (Fig. 2F ). (Fig. 3A) . This effect was found to be specific to the cytokine and not attributable to vector transduction or MSCs since there was no significant therapeutic effect observed in mice treated with MSC-GFP (Fig. 3A) . We then analyzed the therapeutic potential of 
mice treated with MSC-IL-15 survived over 100 days (Fig. 3C) Fig. 3D) .
Furthermore, when tumors were examined histologically, MSC-IL-15 increased tumor cell apoptosis, as shown by TUNEL assay (Fig. 3E) . Massive lymphocyte infiltration, including NK and T cells, was detected in the MSC-IL-15 group compared with MSC-GFP treatment (Fig. 3F) . IL-15 was also able to stimulate expansion and survival of Ȗį T cells. As expected, the intratumor infiltration of Ȗį T cells was also increased after MSC-IL-15 administration (supplementary fig 4) .
In addition, MSC was demonstrated to be able to induce regulatory T cells expansion. 
MSC-IL-15 can home to Tumors and produce IL-15 in vivo
It is well known that MSCs have a strong tropism property toward tumors (14, 15) . To test whether this property existed in our genetically modified MSCs, in vitro migration assays using Transwell plates were performed. We found that only a few cells migrated toward medium, whereas the migration of genetically modified MSCs was significantly increased by the conditional medium of Pan02 cells. Moreover, we confirmed that migration of unmodified MSCs toward the conditional medium was similar to MSC-IL-15, suggesting that IL-15 transfection did not affect the ability of MSC migration (Fig. 4A) . after the administration of MSC-IL-15, the animals were sacrificed and tumor tissues were harvested. We found that these cells accumulated into the tumor bed. To better investigate the intra tumoral persistence and survival of MSC cells, we further detected the bioluminescent imaging of the profile of tumor at 7, 15 and 21 days after MSC-15 injection. Interestingly, we found that initially, MSC-IL-15 was expanded in tumor site, and persistence lasted for more than 21 days with gradual decrease (Fig. 4B) . In addition, PKH-26-positive cells were not observed in the lung, liver, and spleen tissue (data not shown). There was merely modest increase of serum IL-15 level after MSC-IL-15 therapy (Fig.   4C ). Taken together, these data showed that MSC-IL-15 was able to target tumor tissue, and effectively produced intratumoral IL-15.
CD8 + T cells and NK cells were required for MSC-IL-15-mediated antitumor efficacy
To therapy alone (Fig. 5B) . Thus, these studies supported that CD8 + T cells played a major role in the regimen mediated antitumor efficacy whereas NK cells also contributed to the therapeutic efficacy.
Induction of tumor-specific long-term memory response by MSC-IL-15
One of the beneficial characteristics of T-cell-mediated immunity is the development of an effective memory response. To determine whether a tumor-specific (Fig. 6C ). In addition, we also performed ELISPOT assays to determine whether MSC-IL-15 could activate tumor-specific T cells. Our data clearly showed that MSC-IL-15 could effectively promote tumor-specific T cell secreting IFN-Ȗ, and had a much stronger activity than IL-15 treatment (Fig. 6D) . To test whether immunologic memory was induced by MSC-IL-15, the animals survived for 100 days were subsequently rechallenged with the same tumor cells Pan02.
The syngeneic tumor B16 cells were used as controls. Mice cured of Pan02 tumors rejected subsequent challenges with the same tumor, and remained tumor free until the end of the experiment, whereas the mice could not reject syngeneic unrelated B16 tumor in control group (Fig. 6E) , suggesting that mice developed a long-lasting memory against the same tumors, which was consistent with results of CTL assays. Moreover, all mice rechallenged with Pan02 cells showed a long-time survival, and control mice died of progressive tumor growth within 40 days (Fig. 6F) . However, the long-term fate of MSCs which is beyond the scope of this study needs to be further investigated. 
Recently, some studies demonstrated that MSCs had immune-regulation capacity, and thus might contribute to the growth of tumor (34) . Moreover, indeed, we found that It is well known that recombinant adeno-associated virus serotype 2 (rAAV2) has been used in human clinical trials due to low immunogenicity and long-term gene expression. Recently, Yiang GT et al also demonstrated that rAAV2-hIL15 was effective for human glioblastoma treatment (40). However, compared to rAAV2, lentivirus was easy to manipulate and its gene -expression was more stable. Moreover, our aim was to prove the concept that the MSC carried IL-15 has a strong anti-tumor effect. Thus, lentivirus was choosen to deliver IL-15 in our study. rAAV2-IL-15 transfected MSC will be further constructed and the anti-tumor property between them will be evaluated to better characterize whether lentivirus-carried IL-15 has a superior effect than the rAAV2 carried.
Toxic effects related to IL-15 have been described in several reports that high systemic level of IL-15 could lead to NK or T leukemias (41, 42). In the present study, (19, 20) . This property adds advantage toward using MSC to deliver IL-15 in avoiding organ toxicity. 
